Swen JJ - Search Results

1

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: swen jj. Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3. Breast Cancer Res. 2016. PMID: 26738606 Free PMC article. Clinical Trial.

2

Translating pharmacogenomics: challenges on the road to the clinic.

Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ. Swen JJ, et al. PLoS Med. 2007 Aug;4(8):e209. doi: 10.1371/journal.pmed.0040209. PLoS Med. 2007. PMID: 17696640 Free PMC article. Review.

3

Use of plasmid-derived external quality control samples in pharmacogenetic testing.

van der Straaten T, Swen J, Baak-Pablo R, Guchelaar HJ. van der Straaten T, et al. Pharmacogenomics. 2008 Sep;9(9):1261-6. doi: 10.2217/14622416.9.9.1261. Pharmacogenomics. 2008. PMID: 18781854 Free article. Review.

4

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.

Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Swen JJ, et al. Pharmacogenomics. 2010 Nov;11(11):1517-23. doi: 10.2217/pgs.10.121. Pharmacogenomics. 2010. PMID: 21121772

5

Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment.

Swen JJ, Guchelaar HJ, Baak-Pablo RF, Assendelft WJ, Wessels JA. Swen JJ, et al. Pharmacogenet Genomics. 2011 Aug;21(8):461-8. doi: 10.1097/FPC.0b013e3283478173. Pharmacogenet Genomics. 2011. PMID: 21633322

6

Comment: global formulary review: how do we integrate pharmacogenomic information?

Swen JJ, Guchelaar HJ. Swen JJ, et al. Ann Pharmacother. 2011 Jul;45(7-8):1030; author reply 1030-1. doi: 10.1345/aph.1P557a. Epub 2011 Jul 20. Ann Pharmacother. 2011. PMID: 21775697 No abstract available.

7

SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.

Opdam FL, Swen JJ, Wessels JA, Gelderblom H. Opdam FL, et al. Among authors: swen jj. Clin Cancer Res. 2011 Sep 1;17(17):5833-4; author reply 5835-6. doi: 10.1158/1078-0432.CCR-11-1208. Epub 2011 Aug 30. Clin Cancer Res. 2011. PMID: 21878541 No abstract available.

8

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.

Swen JJ, van der Straaten T, Wessels JA, Bouvy ML, Vlassak EE, Assendelft WJ, Guchelaar HJ. Swen JJ, et al. Eur J Clin Pharmacol. 2012 Apr;68(4):363-70. doi: 10.1007/s00228-011-1130-4. Epub 2011 Oct 8. Eur J Clin Pharmacol. 2012. PMID: 21984116 Free PMC article.

9

Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1β gene.

Swen JJ, Baak-Pablo RF, Guchelaar HJ, van der Straaten T. Swen JJ, et al. Clin Chem Lab Med. 2011 Oct 21;50(2):279-84. doi: 10.1515/CCLM.2011.758. Clin Chem Lab Med. 2011. PMID: 22022982

10

The challenges of developing a 'medical-grade' genome.

van der Straaten T, Guchelaar HJ, Swen JJ. van der Straaten T, et al. Among authors: swen jj. Pharmacogenomics. 2012 Mar;13(4):369-72. doi: 10.2217/pgs.12.6. Pharmacogenomics. 2012. PMID: 22379992 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

180 results

Search Page